2. Search Result
Search Result
Results for "

AspS inhibitor

" in MedChemExpress (MCE) Product Catalog:

103

Inhibitors & Agonists

1

Fluorescent Dyes

35

Peptides

2

Inhibitory Antibodies

3

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-111770
    2-Bromohexadecanoic acid
    15+ Cited Publications

    2-Bromopalmitic acid; 2-Bromopalmitate

    		 Pyroptosis Infection Inflammation/Immunology Cancer
    2-Bromohexadecanoic acid (2-Bromopalmitate; 2-BP) is a palmitoylation inhibitor targeting DHHC (Asp-His-His-Cys) protein palmitoyltransferase. 2-Bromohexadecanoic acid inhibits palmitoylation of GSDME-C during pyroptosis and inhibits BAK/BAX-Caspase 3-GSDME pathway-mediated pyroptosis .
    2-Bromohexadecanoic acid
  • HY-12432
    Gilteritinib
    40+ Cited Publications

    ASP2215

    		 FLT3 TAM Receptor Cancer
    Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib
  • HY-16658
    Z-VAD(OMe)-FMK
    Maximum Cited Publications
    200 Publications Verification

    Z-Val-Ala-Asp(OMe)-FMK

    		 Caspase Cancer
    Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor . Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1 .
    Z-VAD(OMe)-FMK
  • HY-148273
    Setidegrasib

    ASP-3082; KRAS G12D inhibitor 17

    		 PROTACs Ras ERK Akt Cancer
    Setidegrasib (KRAS G12D inhibitor 17, ASP3082) is a PROTAC KRAS degrader (DC50: 37 nM). Setidegrasib induces the degradation of G12D-mutation KRAS protein. Setidegrasib suppresses p-ERK, p-AKT, p-S6 levels in AsPC-1 cells. Setidegrasib exhibits anti-tumor activity in various cancer xenograft models in mice. Setidegrasib can be used for the study of KRAS(G12D)-mutated solid tumors. (Blue: VHL ligase ligand (HY-168699); Black: linker (HY-168698); Pink: G12D ligand (HY-168700)) .
    Setidegrasib
  • HY-12290
    Arg-Gly-Asp-Ser
    Maximum Cited Publications
    9 Publications Verification

    RGDS peptide; Fibronectin tetrapeptide

    		 Integrin Inflammation/Immunology
    Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function. Arg-Gly-Asp-Ser directly and specifically bind pro-caspase-8, pro-caspase-9 and pro-caspase-3, while it does not bind pro-caspase-1.
    Arg-Gly-Asp-Ser
  • HY-N0240
    Herbacetin
    5 Publications Verification

    		 Ornithine decarboxylase (ODC) Cancer
    Herbacetin is a natural flavonoid from flaxseed, exerts various pharmacological activities, including antioxidant, anti-inflammatory and anticancer effects . Herbacetin is an Ornithine decarboxylase (ODC) allosteric inhibitor, directly binds to Asp44, Asp243, and Glu384 on ODC. Ornithine decarboxylase (ODC) is a rate-limiting enzyme in the first step of polyamine biosynthesis .
    Herbacetin
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
    2 Publications Verification

    Cyclo(RGDfC)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)
  • HY-19568
    Peficitinib
    10+ Cited Publications

    ASP015K; JNJ-54781532

    		 JAK Inflammation/Immunology
    Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .
    Peficitinib
  • HY-10423
    OSI-027
    10+ Cited Publications

    ASP7486

    		 mTOR Autophagy Cancer
    OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive mTOR kinase activity inhibitor with an IC50 of 4 nM. OSI-027 targets both mTORC1 and mTORC2 with IC50s of 22 nM and 65 nM, respectively .
    OSI-027
  • HY-14894
    Ipragliflozin
    5+ Cited Publications

    ASP1941

    		 SGLT Metabolic Disease
    Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .
    Ipragliflozin
  • HY-P990774
    Verekitug

    ASP-7266; TRAB-1; UPB-101

    		 Interleukin Related Inflammation/Immunology
    Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .
    Verekitug
  • HY-167874
    ASP-8731

    		Heme Oxygenase (HO) NF-κB Transmembrane Glycoprotein Cardiovascular Disease
    ASP-8731 is an orally active BACH1 inhibitor. ASP-8731 activates antioxidant, anti-inflammatory and globin gene pathways by relieving the inhibitory effect of BACH1 on NRF2-mediated gene transcription. ASP-8731 significantly upregulates the expression of HMOX1, FTH1 and various globins (such as HGB, HBG, HBA), increases fetal hemoglobin (HbF) levels, and effectively induces F-cell production in hydroxyurea-unresponsive cells. Meanwhile, ASP-8731 reduces inflammatory responses and white blood cell counts by downregulating VCAM1, ICAM-1 and the phosphorylation level of NF-κB(p65), and blocks heme-induced glutathione depletion and microcirculatory stasis. ASP-8731 holds potential for inhibiting sickle cell disease and related hematological disorders .
    ASP-8731
  • HY-12432A
    Gilteritinib hemifumarate
    40+ Cited Publications

    ASP2215 hemifumarate

    		 FLT3 TAM Receptor Cancer
    Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.
    Gilteritinib hemifumarate
  • HY-13326
    ASP3026
    5+ Cited Publications

    		 Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK Cancer
    ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research .
    ASP3026
  • HY-19903
    ASP-9521
    3 Publications Verification

    		 17β-HSD Cancer
    ASP-9521 is a potent, selective and orally available AKR1C3 inhibitor with an IC50 of 11 nM for human AKR1C3.
    ASP-9521
  • HY-19983
    ASP5878
    1 Publications Verification

    		 FGFR Cancer
    ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity .
    ASP5878
  • HY-P10004
    Z-Ala-Ala-Asp-CMK
    2 Publications Verification

    Z-AAD-CMK

    		 Caspase Apoptosis Reactive Oxygen Species (ROS) Interleukin Related Inflammation/Immunology Cancer
    Z-Ala-Ala-Asp-CMK (Z-AAD-CMK) is a selective granzyme B inhibitor. By binding to the active site of granzyme B, Z-Ala-Ala-Asp-CMK blocks its proteolytic function. Z-Ala-Ala-Asp-CMK has anti-inflammatory activity and can be used in the research of inflammatory diseases and cancer .
    Z-Ala-Ala-Asp-CMK
  • HY-P10925A
    (Z)-Zolucatetide

    (Z)-FOG-001; I-67

    		 β-catenin Cancer
    (Z)-Zolucatetide (I-67) is a β-catenin inhibitor with IC50 ≤50 nM. (Z)-Zolucatetide's sequence is Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys3-PyrS2-3Thi-BztA-GlnR3-Ala-NH2. (Z)-Zolucatetide can be used for cancer research .
    (Z)-Zolucatetide
  • HY-19729
    Naquotinib
    5 Publications Verification

    ASP8273

    		 EGFR Cancer
    Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.
    Naquotinib
  • HY-152086
    DRP1i27

    		Dynamin Cardiovascular Disease
    DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .
    DRP1i27
  • HY-P1613A
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA

    Cyclo(RGDfV) TFA; C(RGDfV) TFA

    		 Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) (Cyclo(RGDfV) (TFA))is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) can be used for the research of acute myeloid leukemia .
    Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA
  • HY-112415
    Lith-O-Asp
    3 Publications Verification

    		 Sialyltransferase Metabolic Disease
    Lith-O-Asp is a sialytransferase (ST) inhibitor, with IC50s of 12-37 μM.
    Lith-O-Asp
  • HY-112860
    Asp-AMS

    		Aminoacyl-tRNA Synthetase Mitochondrial Metabolism Metabolic Disease
    Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme.
    Asp-AMS
  • HY-113953
    Z-Asp-CH2-DCB

    		Caspase Apoptosis Inflammation/Immunology
    Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development .
    Z-Asp-CH2-DCB
  • HY-P0322
    GRGDSPK

    EMD 56574

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
    GRGDSPK
  • HY-172815
    IDB-001

    		JNK Eukaryotic Initiation Factor (eIF) p38 MAPK Cancer
    IDB-001 is a human ribosomal peptidyl transferase center (PTC) inhibitor that induces conformational changes and blocks translational elongation in specific sequence contexts through complementary interactions with Asp/Glu residues in nascent polypeptides. IDB-001 preferentially stalls ribosomes at positions containing acidic peptide motifs, thereby inhibiting cancer cell proliferation, and activates the integrated stress response via eIF2α phosphorylation at high concentrations. In addition, IDB-001 mildly triggers ribotoxic stress responses through phosphorylation of JNK and p38. IDB-001 has been applied to mechanistic studies of triple-negative breast cancer .
    IDB-001
  • HY-122015
    ASP2905

    		Potassium Channel Neurological Disease
    ASP2905 is an orally active potassium channel Kv12.2 inhibitor encoded by the Kcnh3/BEC1 gene. ASP2905 can cross the blood-brain barrier and has antipsychotic activities .
    ASP2905
  • HY-19803
    Naquotinib mesylate
    5 Publications Verification

    ASP8273 mesylate

    		 EGFR Cancer
    Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.
    Naquotinib mesylate
  • HY-103348
    Boc-Asp(OMe)-fluoromethyl ketone

    Boc-Asp(OMe)-FMK

    		 Caspase Inflammation/Immunology
    Boc-Asp(OME)-Fluoromethyl Ketone is a broad range caspase inhibitor that inhibits Fas-mediated phagocytosis and oxidative rupture inhibition, but does not affect the chemotactic activity of IL-8 .
    Boc-Asp(OMe)-fluoromethyl ketone
  • HY-152086A
    DRP1i27 dihydrochloride

    		Dynamin Cardiovascular Disease
    DRP1i27 dihydrochloride is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 dihydrochloride binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 dihydrochloride targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury .
    DRP1i27 dihydrochloride
  • HY-153793
    Alcudacigib

    DGKζ-IN-1

    		 DGK IFNAR Interleukin Related ERK Cancer
    Alcudacigib (ASP1570; DGKζ-IN-1) is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC50 of 4.7 nM against human DGKζ and an IC50 of 3.0 nM against mouse DGKζ. Alcudacigib selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib enhances the anti-tumor functions of T cells and NK cells. Alcudacigib can be used for the research of advanced/metastatic solid tumors .
    Alcudacigib
  • HY-P2300A
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
    2 Publications Verification

    Cyclo(RGDfC) TFA

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA
  • HY-P4896
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro

    		Integrin Cancer
    FITC-Ahx Gly Arg Gly Asp Ser Pro is a GRGDSP (HY-P0290) coupled to FITC. GRGDSP is an integrin inhibitor that can inhibit the adherence of tumor cells to endothelial cells of blood vessels and limit its metastasis .
    FITC-Ahx-Gly-Arg-Gly-Asp-Ser-Pro
  • HY-19568R
    Peficitinib (Standard)

    ASP015K (Standard); JNJ-54781532 (Standard)

    		 Reference Standards JAK Inflammation/Immunology
    Peficitinib (Standard) is the analytical standard of Peficitinib. This product is intended for research and analytical applications. Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .
    Peficitinib (Standard)
  • HY-P0178
    LXW7

    		Integrin Inflammation/Immunology
    LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
    LXW7
  • HY-132966
    ASP2453
    1 Publications Verification

    		 Ras ERK Cancer
    ASP2453 is a potent, selective and orally active KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 value of 40 nM.
    ASP2453
  • HY-136727
    Ac-LEVD-CHO
    1 Publications Verification

    		 Caspase Cancer
    Ac-LEVD-CHO is a caspase-4 inhibitor. Ac-LEVD-CHO is a peptide with the sequence of Ac-Leu-Glu-Val-Asp-al .
    Ac-LEVD-CHO
  • HY-112535
    (R)-Lith-O-Asp

    α-2,3-Sialyltransferase-IN-1

    		 Sialyltransferase Inflammation/Immunology Cancer
    (R)-Lith-O-Asp (α-2,3-Sialyltransferase-IN-1) is a noncompetitive α-2,3-sialyltransferase inhibitor with an IC50 of 6 μM.
    (R)-Lith-O-Asp
  • HY-N15723
    Dipsacus saponin A

    		Others Others
    Dipsacus saponin A is an orally active triterpenoid saponin found in the roots of Dipsacus asper. Dipsacus saponin A promotes bone repair by regulating osteoblast activity and inhibiting osteoclast function. Dipsacus saponin A is promising for research of bone diseases such as fracture healing and osteoporosis .
    Dipsacus saponin A
  • HY-12432R
    Gilteritinib (Standard)

    ASP2215 (Standard)

    		 Reference Standards FLT3 TAM Receptor Cancer
    Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib (Standard)
  • HY-153793A
    Alcudacigib TFA

    DGKζ-IN-1 TFA

    		 DGK IFNAR Interleukin Related ERK Cancer
    Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ (DGKζ) inhibitor, with an IC50 of 4.7 nM against human DGKζ and an IC50 of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein. Alcudacigib TFA enhances the anti-tumor functions of T cells and NK cells. Alcudacigib TFA can be used for the research of advanced/metastatic solid tumors .
    Alcudacigib TFA
  • HY-P0178A
    LXW7 TFA

    		Integrin Inflammation/Immunology
    LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect .
    LXW7 TFA
  • HY-124428
    ASP6537

    FK881

    		 COX Cardiovascular Disease
    ASP6537 is a potent and selective rhCOX-1 inhibitor with an IC50 of 0.703 nM. ASP6537 has the potential for cardiovascular disease research .
    ASP6537
  • HY-W142117
    H-Asp(AMC)-OH

    		Fluorescent Dye Others
    H-Asp(AMC)-OH, a amino acid derivative, is a fluorescent dye. H-Asp(AMC)-OH dose not inhibit glycine transport at a concentration of 0.25 mM .
    H-Asp(AMC)-OH
  • HY-P1613
    Cyclo(Arg-Gly-Asp-D-Phe-Val)

    Cyclo(RGDfV); C(RGDfV)

    		 Integrin Apoptosis Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Val) (Cyclo(RGDfV)) is an integrin αvβ3 inhibitor. Cyclo(Arg-Gly-Asp-D-Phe-Val) has antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) can be used for the research of acute myeloid leukemia .
    Cyclo(Arg-Gly-Asp-D-Phe-Val)
  • HY-110176
    ASP2535

    		GlyT Neurological Disease
    ASP2535 is a potent, orally bioavailable, selective, brain permeable and centrally-active glycine transporter-1 (GlyT1) inhibitor. ASP2535 can improve cognitive impairment in animal models of schizophrenia and Alzheimer's disease .
    ASP2535
  • HY-12432S1
    Gilteritinib-d8

    ASP2215-d8

    		 FLT3 TAM Receptor Cancer
    Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib-d8
  • HY-19568B
    Peficitinib hydrochloride

    ASP015K hydrochloride; JNJ-54781532 hydrochloride

    		 JAK Inflammation/Immunology
    Peficitinib (ASP015K) hydrochloride is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .
    Peficitinib hydrochloride
  • HY-120496
    Clofutriben

    ASP3662

    		 11β-HSD Neurological Disease Metabolic Disease
    Clofutriben (ASP3662) is a selective, orally active and brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with Ki values of 5.3 nM (human), 2.6 nM (mouse), and 23 nM (rat). Clofutriben inhibits conversion of inactive glucocorticoids to active glucocorticoids, reducing intracellular glucocorticoid exposure. Clofutriben ameliorates neuropathic pain, and restores muscle pressure thresholds in rodent models, while lacking effects in inflammatory pain .
    Clofutriben
  • HY-142031
    4-Piperidinecarboxamide

    		Bacterial Infection
    4-Piperidinecarboxamide is a mycobacterial aspartyl-tRNA synthetase (AspS) inhibitor. 4-Piperidinecarboxamide is a promising anti-tuberculosis (TB) agent .
    4-Piperidinecarboxamide

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: